Taxotere Hair Loss Lawsuit News

Scientific Studies Point to Taxotere Hair Loss

Sanofi may have been aware of scientific studies that indicated that Taxotere hair loss may not be only temporary

Monday, December 18, 2017 - Taxotere, manufactured by Sanofi, is the most popular anti-cancer chemotherapy drug on the market, however, studies have linked the drug to Alopecia, a form of permanent hair loss. Oncologists recommend Taxotere to their patients that suffer from cancer of the breast, lung, stomach, head neck and prostate gland. Temporary hair loss is a common side effect of chemotherapy drugs and is to be expected. The total baldness of the head hair, eyebrows, eyelashes, and pubic hair however in most cases, the hair loss is only temporary and hair is anticipated to grow back in a few months after chemotherapy stops. Cancer patients are routinely advised that temporary hair loss will be a side effect of taking receiving chemotherapy. A cancer patient starts to realize that something is wrong when their hair fails to grow back years after chemotherapy stops. Patients began to realize they had may have been lied to and that their hair loss may be permanent and never grow back.

It is hard to tell exactly how many women were treated with Taxotere without being told of the Alopecia side effect of the drug. What is clear is that the company has known about them for some time. Studies conducted in 2005 showed that approximately 75% of breast cancer patients were given Taxotere, and over 9% of them experience permanent hair loss. Sanofi waited until 2015 to issue any type of warning to consumers. Had cancer patients been aware of the increased risk of Alopecia they may have decided to use another drug or forego chemotherapy entirely. At the very least, patients have a right to know all of the known effects of the drugs they are given.

Other studies clearly point to Taxotere as causing their permanent hair loss as well. From 1 January 2007 to 1 January 2011, The Annals of Oncology published and confirmed that patients given Taxotere experienced total hair loss from Alopecia. In another instance, the Food and Drug Administration (FDA) issued a warning to Sanofi-Aventis, refuting the company's claim of Taxotere's effectiveness and that the company's reprint citing a study in the Journal of Oncology was "false and misleading" and that Taxotere was in fact no more effective in treating breast cancer than Taxol.

A 2014 study by the National Cancer Research Institute found the number Taxotere patients suffering from permanent baldness at around 10-15%. Another study collected data from 500 Taxotere patients over a period ten-years and found that about 6% developed permanent Alopecia. The study was conducted in 2016 by Dr. Scot Sedlacek of the Rocky Mountain Cancer Center in Colorado.

These studies and others are being cited by plaintiffs suing Sanofi in Taxotere hair loss lawsuits for their negligence in failing to warn consumers of the side effect of permanent Alopecia. Thousands of women have had their lives irreparably damaged when they failed to regrow hair months and years after stopping chemotherapy. Total hair loss has affected their self-esteem, body image, and caused chronic depression leading to the loss of their jobs. Women report Taxotere hair loss depression so severe that they are unable to leave their homes for fear of being ridiculed and cannot lead a basic and normal life.

More Recent Taxotere Hair Loss Lawsuit News:

Lawyers for Taxotere Hair Loss Lawsuits

Onder, Shelton, O'Leary & Peterson, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O'Leary & Peterson has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.